Pacific Biosciences
PACB
226 hedge funds and large institutions have $266M invested in Pacific Biosciences in 2025 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 57 increasing their positions, 74 reducing their positions, and 35 closing their positions.
148% more call options, than puts
Call options by funds: $4.29M | Put options by funds: $1.73M
6% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 35
0% more funds holding
Funds holding: 226 → 226 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19.17% less ownership
Funds ownership: 94.77% → 75.6% (-19%)
23% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 74
81% less capital inflows, than outflows
Capital inflows: $12.4M | Capital outflows: $65.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.59M |
| 2 |
Koss-Olinger Consulting
Gainesville,
Florida
|
+$1.53M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.22M |
| 4 |
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$780K |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
+$749K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$22.8M |
| 2 |
Bank of New York Mellon
New York
|
-$6.66M |
| 3 |
Goldman Sachs
New York
|
-$4.49M |
| 4 |
Walleye Capital
New York
|
-$3.56M |
| 5 |
Morgan Stanley
New York
|
-$3.5M |
PACB Hedge Fund Activity: Q1 2025 in Review
226 of the 7,489 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2025, worth a combined $266M — down 44% from $475M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PACB positions and 35 closed out — a net gain of 2 holders — while 57 added to existing stakes and 74 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.59M. The largest seller was Millennium Management, cutting an estimated $22.8M.
- 226 institutional investors held Pacific Biosciences (PACB) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $266M of Pacific Biosciences stock for Q1 2025, down 44% quarter-over-quarter.
- 37 funds opened new Pacific Biosciences positions in Q1 2025 and 35 closed out, a net change of +2 holders.
- The largest Pacific Biosciences buyer in Q1 2025 was Vanguard Group, an estimated $1.59M added.
- The largest Pacific Biosciences seller in Q1 2025 was Millennium Management, an estimated $22.8M sold.
Based on aggregated 13F filings for Q1 2025.